Biocytogen Pharmaceuticals (Beijing) Co Ltd

02315

Company Profile

  • Business description

    Biocytogen Pharmaceuticals (Beijing) Co Ltd is a biopharmaceutical and pre-clinical research services company. It has two Core Products, YH003 and YH001. YH003 is a recombinant humanized agonistic anti-Cluster of Differentiation 40 (CD40) Immunoglobulin G2 (IgG2) monoclonal antibody and YH001 is a recombinant humanized anti-CTLA-4, a protein receptor expressed constitutively on T cells that functions as an immune checkpoint and downregulates immune responses, Immunoglobulin G1 (IgG1) monoclonal antibody. YH003 is being developed for pancreatic ductal adenocarcinoma, melanoma, and other developed solid tumors. YH001 is being developed for hepatocellular carcinoma (HCC), non-small-cell lung carcinoma (NSCLC), and other solid tumors.

  • Contact

    12 Baoshen South Street
    Daxing Bio-Medicine Industry Park
    Daxing District
    Beijing
    CHN

    T: +86 1056967680

    https://www.biocytogen.com.cn

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2025

    Employees

    1,117

Stocks News & Analysis

stocks

Insignia Financial: Revised deal still attractive

The offer price is well above our fair value.
stocks

Undervalued ASX income play

Major development projects remain on schedule.
stocks

Going into earnings, is Alphabet stock a buy, a sell, or fairly valued?

With the monetization of GenAI, here’s what we think of Alphabet’s stock

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries9,001.4059.900.67%
CAC 407,827.3482.931.07%
DAX 4024,214.87172.970.72%
Dow JONES (US)44,502.44179.370.40%
FTSE 1009,058.2734.460.38%
HKSE25,490.47360.441.43%
NASDAQ20,892.6981.49-0.39%
Nikkei 22541,171.321,396.403.51%
NZX 50 Index12,794.0639.68-0.31%
S&P 5006,309.624.020.06%
S&P/ASX 2008,737.2060.000.69%
SSE Composite Index3,582.300.440.01%

Market Movers